Meet Our People
Experienced Drug Development and Bioinformatics Leaders
Nan Bing, M.D., Ph.D.
Co-founder, Chairman, and CEO
Nan Bing, M.D., Ph.D.
Co-founder, Chairman, and CEO
Dr. Bing serves as the Co-founder, Chairman and CEO of D2M Biotherapeutics. Driven by his 20 years of experiences and insights in applying genetics data for targets and therapeutics development, Dr. Bing co-founded D2M in 2020.
Prior to D2M, Dr. Bing served as Senior Director, Human Genetics & Target Science at Pfizer. Under his leadership, Dr. Bing’s genetics team played critical scientific and strategic roles in Pfizer’s immune & inflammation R&D program assessment and evaluation. His group provided important decision-making contributions on several high-profile assets currently in clinic development at Pfizer. Before his tenure at Pfizer, Dr. Bing served as Investigator and Principal Scientist in Genetics Research group at GlaxoSmithKline.
Dr. Bing holds his Ph.D of Genetics and Bioinformatics from Virginia Tech, and M.D. from China Medical University.
Dong Zhang, Ph.D.
Co-founder, CSO
Dong Zhang, Ph.D.
Co-founder, CSO
Dr. Zhang's is the Co-founder and Chief Scientific Officer at D2M Biotherapeutics. Trained as an immunologist, Dr. Zhang has 20 years of drug discovery & development experience in cancer immunotherapy.
Before co-founding D2M, he served as Director, Immuno- Oncology of EMD Serono Research and Development Institute/Merck KGaA. During his 15-year tenure at Merck KGaA, where he progressively shouldered key responsibilities in the Immuno-Oncology pipeline. His significant contributions are highlighted by leading 10 cross-functional Discovery Project teams as Team Leader, with four programs advancing into clinical development, including the marketed Bavencio® (anti- PD-L1, Avelumab®).
Holding a Ph.D. from Chinese Academy of Science, and a B.Sc. in biochemistry from Jilin University, Dr Zhang’s academic prowess is complemented by nine-year post-doc training at Dr. Judy Lieberman’s lab at Harvard Medical School.
Sheng Yin, Ph.D.
CTO, D2M China General Manager
Sheng Yin, Ph.D.
CTO, D2M China General Manager
Dr. Yin is Chief Technology Officer, and General Manager in China at D2M. As the CTO, he has over 15 years of experience in CMC and IND enabling study & development. In the past, he has successfully delivered multiple IND applications and PD technology transfers, including establishment of the first 10,000 L antibody stainless-steel tank production in China.
Prior to joining D2M, he served as Deputy General Manager at Hengrui-Suzhou Suncadia Biopharmaceuticals, overseeing early- stage process development and late-stage tech transfer and scale-up. Before Hengrui, Dr. Yin held a progressive role in CMC, process development, and analytical science at several biopharma companies including Genetech/Wuxi Biologics/BI (China) and I-mab.
Dr. Yin holds a Ph.D. in Biochemistry and Molecular Biology and a B.S. in Biochemistry from UCLA.
Karl Qin, M.B.A.
CBO
Karl Qin, M.B.A.
CBO
Mr. Qin has over 28 years of management experience at leading biopharma companies and top medical institutions. Mr. Qin has negotiated and closed over 30 commercial transactions with the global healthcare organizations including Pfizer, Eli Lilly, BMS, Myriad Genetics, Millennium, Bausch Lomb and Innovent.
Prior to joining D2M as Chief Business Officer, he was CBO and COO at MediBoston Inc., a venture backed company focused on ADC therapeutics. Mr. Qin also served in senior management positions at several biopharma companies including Genzyme/Sanofi and CDS. Mr. Qin started his career with MD Anderson Cancer Center. As Director of Technology Commercialization, he managed MD Anderson’s venture start- ups and technology licensing.
Mr. Qin hold an MBA from Rice University; M.S. in Cellular Biology from University of Massachusetts, Amherst, and B.S. in Virology from Wuhan University.
Advisors
Tony Ho, M.D.
Scientific Advisor
Tony Ho, M.D.
Scientific Advisor
Dr. Tony Ho has 20-years of comprehensive R&D experience in the biotechnology and pharmaceutical industry. His most recent role was as the Executive Vice President, Research and Development at CRISPR Therapeutics, where he spearheaded R&D initiatives spanning the entire spectrum of development phases, encompassing discovery, early and late-stage clinical development, and regulatory affairs. Notably, Dr. Ho played a pivotal role in the creation of the groundbreaking CRISPR-based therapy known as Casgevy, a pioneering achievement in the field. Dr. Ho has held several roles of increasing seniority at AstraZeneca, most recently serving as the Senior Vice President and Head of Oncology Integration and Innovation. At AstraZeneca, he led the development and commercialization of two key drugs: LYNPARZA, a PARP inhibitor for ovarian cancer, IMFINZI, a PD-L1 inhibitor AstraZeneca’s first immuno-oncology drug for bladder cancer and IMJUDO, a anti-CTLA4 for lung cancer. Before that, Dr. Ho was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., and led multiple development programs, including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma. Previously, he was the Co- Founder and Chief Scientific Officer of Neuronyx, a regenerative medicine company.
Dr. Ho is also an adjunct Associate Professor at both the University of Pennsylvania and Johns Hopkins University. He earned his M.D. from the Johns Hopkins University School of Medicine and his B.S. in Electrical Engineering at the University of California, Los Angeles.
Kai W. Wucherpfennig, M.D., Ph.D.
Scientific Advisor
Kai W. Wucherpfennig, M.D., Ph.D.
Scientific Advisor
Dr. Kai W. Wucherpfennig is Chair of Cancer Immunology and Virology, and Director of the Center for Cancer Immunotherapy Research at Dana-Farber Cancer Institute. He is the Nancy Lurie Marks Professor of Neurology in the Field of Medical Oncology; Professor of Neurology at Brigham and Women’s Hospital and Harvard Medical School; a Professor of Immunology at Harvard Medical School; and an Associate Member of Broad Institute of MIT and Harvard.
Dr. Wucherpfennig is an elected fellow, American Society for the Advancement of Science; an elected member of American Society for Clinical Investigation; an elected member, Henry Kunkel Society, Rockefeller University.
Dr. Wucherpfennig received his MD in 1986 and his PhD in 1987 from the University of Goettingen, Germany. He completed research fellowships at Brigham and Women's Hospital and the Department of Molecular and Cellular Biology, Harvard University. In 1995, he joined Dana-Farber Cancer Institute, where he is principally involved in basic laboratory research that focuses on T cell immunology and the role of T cells in cancer immunology.